Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b/2a Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection

NCT06016088 is registered in ClinicalTrials.gov with Respirion Pharmaceuticals Pty Ltd as lead sponsor.

NCT NCT06016088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06016088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b/2a Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
April 1, 2024
Completion date
June 22, 2026
Enrollment
71 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis lung, pseudomonas aeruginosa, respiratory infections, recurrent, chronic